Skip to content

PREDICTing long-term clinical outcomes by Optical coherence tomography assessment of plaque characteristics in the non-Revascularized coronary artery 2

PREDICTing long-term clinical outcomes by Optical coherence tomography assessment of plaque characteristics in the non-Revascularized coronary artery 2 - PREDICTOR 2

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs052250207
Enrollment
560
Registered
2026-01-28
Start date
2026-04-28
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic heart disease (stable angina, unstable angina, NSTEMI, STEMI) Myocardial Ischemia

Interventions

Perform percutaneous coronary intervention (PCI) using standard techniques, and implant an everolimus-eluting stent to completely cover the vulnerable plaque.

Sponsors

Yamaji Kyohei
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Subjects who meet all of the following criteria will be included: 1. Aged 18 years or older at the time of obtaining informed consent. 2. Signed informed consent has been obtained from the subject. 3. Have at least one non-ischemic moderate stenosis that meets all of the following criteria: 1. Visual assessment on coronary angiography shows a vessel diameter of >=2.5 mm and a stenosis >=50%. 2. No functional ischemia has been diagnosed. 3. Vulnerable plaque is identified by OCT (optical coherence tomography).

Exclusion criteria

Exclusion criteria: Subjects who meet any of the following criteria will be excluded: 1. Have a serious underlying disease with an expected prognosis of less than one year. 2. Have cardiogenic shock or decompensated heart failure requiring endotracheal intubation, vasopressors, or hemodynamic support devices. 3. Have a history of or are scheduled to undergo coronary artery bypass grafting (CABG). 4. Have a left main coronary artery lesion. 5. Have a history of bleeding tendency or a known coagulation disorder. 6. Have a known allergy to any of the drugs required in this protocol, including aspirin, P2Y12 inhibitors (prasugrel, clopidogrel, ticagrelor), heparin, or iodinated contrast agents (if not adequately managed by premedication).

Design outcomes

Primary

MeasureTime frame
The incidence of target vessel failure (TVF), defined as a composite endpoint of cardiovascular death, target vessel myocardial infarction, and clinically indicated target vessel revascularization during a 3-year follow-up.

Secondary

MeasureTime frame
The 3-year incidence of the following events: Death Cardiovascular death Target vessel myocardial infarction Periprocedural myocardial infarction Non-periprocedural myocardial infarction Any myocardial infarction Target lesion revascularization Target vessel revascularization Non-target lesion revascularization Non-target vessel revascularization Any coronary artery revascularization Definite stent thrombosis Probable stent thrombosis For all myocardial infarctions, it will be assessed whether they are periprocedural myocardial infarctions. Similarly, for all revascularizations, it will be assessed whether they are clinically indicated. The relationship between the presence of vulnerable plaque, as determined by AI, and clinical events will be evaluated.

Contacts

Public ContactKyohei Yamaji

Kyoto University Hospital

yamaji@kuhp.kyoto-u.ac.jp+81-75-751-4255

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Sep 19, 2026